Clinical Trial Update: Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing tislelizumab plus GX versus tislelizumab plus GP in relapsed/refractory nasopharyngeal carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING